
|Videos|January 30, 2023
Combination Ruxolitinib and Selinexor for the Treatment of Naïve Myelofibrosis
Author(s)Joshua Richter, MD, Srdan Verstovsek, MD, PhD
Srdan Verstovsek, MD, reviews data presented at ASH 2022 on combination ruxolitinib and selinexor for the frontline treatment of myelofibrosis.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
Gedatolisib Combinations Double PFS in PIK3CA-Mutant Breast Cancer
5



































